TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04769206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: 4mg daily titrating up to 8mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 pill a day for 4 weeks, 2 pills a day for 8 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS 7000
Description: The FDA-approved TENS 7000 device will be used for Trans-auricular vagus nerve stimulation (TaVNS) during a period of enhanced vascular oxidative stress. This device will be supplemented with ear clip electrodes. The site of the stimulation for such electrodes are the tragus or concha. The device will have built in safety controls to minimize additional risks to the subjects (as per FDA guidance on stimulators). We will use typical stimulation conditions (30 Hz, 300 µs) and amplitude dependent on perception threshold.
Study: NCT06154447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-828
Description: Suspension for Oral Administration
Study: NCT05499871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gait retraining intervention
Description: Participants will receive a training to modify their footstrike pattern toward a more forefoot strike and increase their cadence by 7.5%.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transition to minimalist footwear.
Description: Participants will receive a running minimalist footwear.
Study: NCT06272825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: VR-based exercise program will be applied in addition to the conventional rehabilitation program, 5 days a week for a total of 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional rehabilitation
Description: The conventional exercise program will include 20 minutes(Transcutaneous Electrical Nerve Stimulation) TENS with conventional method, 4 minutes continue ultrason, 20 minutes hot pack.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional rehabilitation
Description: The conventional exercise program will include 20 minutes(Transcutaneous Electrical Nerve Stimulation) TENS with conventional method, 4 minutes continue ultrason, 20 minutes hot pack.
Study: NCT05720429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational program
Description: A psychoeducational program consisting of 11 one-hour sessions, with a weekly or biweekly frequency, each one regarding specific tools and skills to promote emotional well-being, self-care, and the ability to deal with stressful situations. They are conducted by community psychologists, who will give a brief theoretical introduction and then conduct practical group exercises that apply the concepts introduced. Every session ends with a relaxation exercise and some habits that the participants can incorporate into their daily life.~Session Index: (1) Emotional management;(2) Thought management; (3) Stress management; (4) Communication skills, active listening, and empathy; (5) Self-care; (6) Individual/group self-esteem; (7) Anxiety/coping with panic. Mindfulness; (8) Activating motivation; (9) Problem-Solving; (10) Positive psychology and emotional intelligence; (11) Emotional expression through art.
Study: NCT05022888

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regional tissue saturation
Description: tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle. The NIRS probe will be used in these areas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: regional tissue saturation
Description: tissue oxygen saturation measured from 4 different regions defined on the trapezius muscle. The NIRS probe will be used in these areas.
Study: NCT06058273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bruni® training
Description: 10 sessions (7 individual and 3 group) based on the Bruni method, which was born as a method for the artistic voice (rock, pop, gospel, R\&B, grunge, metal), acting and dubbing. It is a method based on the didactic desire to lead any artist to the ability to produce various types of noise, specifically generically supraglottic, predominantly arytenoid and falsechordal emissions, providing the perceptive, proprioceptive and praxis tools to safely emit and manage the many sounds generated from a supraglottic source
Study: NCT04855331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic pancreatoduodenectomy
Description: Laparoscopic pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open pancreatoduodenectomy
Description: Open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer.
Study: NCT05401461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evening mobilisation
Description: Evening mobilisation delivered between (19.00 and 21.00) according to standardised procedures and established safety criteria. The intervention will begin on day 1 of admission or the first evening following recruitment. Mobilisation will be defined as a score of ≥ 2 on the Manchester mobility score (sit on the edge of the bed or higher), with actual mobilisation level achieved and duration of intervention based on clinical decision of the mobilisation therapists. Patients will also be offered the opportunity to engage in activities which may be part of their normal evening routines (e.g. brushing teeth, reading or watching television). The intervention will be carried out for up to seven consecutive evenings. The evening mobilisation will be delivered in addition to any input from the MDT during normal daily working hours and will not replace any standard therapy.
Study: NCT05730855

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time Polymerase Chain Reaction technique
Description: Real-time Polymerase Chain Reaction technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time Polymerase Chain Reaction technique
Description: Real-time Polymerase Chain Reaction technique

Intervention type: DIAGNOSTIC_TEST
Intervention: Real-time Polymerase Chain Reaction technique
Description: Real-time Polymerase Chain Reaction technique
Study: NCT06198998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CorVad Percutaneous Ventricular Assist System
Description: The CorVad Percutaneous Ventricular Assist System provides hemodynamics support for intraoperative protection during high-risk percutaneous coronary intervention.
Study: NCT05859308

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Pixel Plucker
Description: A virtual reality task where participants wear the Virtual Reality headset and respond to targets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rock Steady Boxing
Description: An in-person boxing class designed for individuals with Parkinson's disease.
Study: NCT06314126

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-Chiro-Inositol
Description: Patients in the experimental group will receive 1200 mg of oral D-Chiro-Inositol per day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group will receive 1200 mg of placebo per day.
Study: NCT03883763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine S75:R25 plus 8% glucose
Description: Spinal anesthesia, 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine S50:R50 plus 8% glucose
Description: Spinal anesthesia, 20 mg
Study: NCT05226117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan is a humanized monoclonal antibody (mAb) with a hydrolyzable linker through which SN-38 is conjugated to the humanized mAb hRS7 IgG1κ to enhance the delivery of SN-38 to Trop-2- expressing tumors while reducing systemic toxicity. SN-38 is the active metabolite of irinotecan. Sacituzumab govitecan is administered at 10 mg/kg as an IV infusion on days 1 and 8 of a 21- day cycle till progression, toxicity or withdrawal of consent
Study: NCT06154447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-828
Description: Suspension for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-828
Description: Suspension for Oral Administration
Study: NCT05002504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapy sessions
Description: Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Therapy sessions
Description: Seven treatment sessions were carried out with the balance and coordination therapeutic exercise techniques (group 3) most frequently used for the treatment of these pathologies; seven sessions of craniosacral therapy (group 2) as corrective and preventive in possible alterations during infant neurodevelopment and finally seven sessions simulating craniosacral therapy on a placebo group (group 1) as a control of the treatments used.
Study: NCT05054816

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational adaptive directional microphone strategy
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with the investigational adaptive directional microphone strategy that is expected to improve sound quality of speech in a car.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator omnidirectional microphone strategy
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator omnidirectional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
Study: NCT06154447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-828
Description: Suspension for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-828
Description: Suspension for Oral Administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for Oral Administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Solution for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor
Description: Tablets for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor
Description: Tablets for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor
Description: Tablets for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-118
Description: Tablets for Oral Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-118
Description: Tablets for Oral Administration
Study: NCT05054816

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator fixed directional microphone strategy
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with the comparator fixed directional microphone strategy that is used with the default settings as specified in the manufacturer's fitting software.
Study: NCT06154447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-118
Description: Tablets for Oral Administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension and Tablets for Oral Administration
Study: NCT03817021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECE Provider
Description: Provide online training for Head Start educators

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECE Provider
Description: Provide online training for Head Start educators

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECE Provider
Description: Provide online training for Head Start educators

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECE Provider
Description: Provide online training for Head Start educators

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Intervention
Description: Coach parents remotely to educate them on responsive feeding and parenting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Intervention
Description: Coach parents remotely to educate them on responsive feeding and parenting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Intervention
Description: Coach parents remotely to educate them on responsive feeding and parenting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Intervention
Description: Coach parents remotely to educate them on responsive feeding and parenting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child intervention
Description: Through classrooms lessons cover 3 topics: 1) self-regulation, 2) hunger and fullness, and 3) mindfulness in eating and attention control practices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child intervention
Description: Through classrooms lessons cover 3 topics: 1) self-regulation, 2) hunger and fullness, and 3) mindfulness in eating and attention control practices
Study: NCT04794517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Dapagliflozin 10 mg/die will be administered orally for six-weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet/die will be administered orally for six-weeks.
Study: NCT06611501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Metformin dosage titrated from 500 mg/daily for 2 weeks, then 1000 mg/daily for 2 weeks, 1500 mg/daily for 2 weeks, and then achieving 2000 mg/daily for a duration of 6 months of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet orally with evening meal for 2 weeks, then 1 tablet twice daily for 2 weeks, then 3 tablets split twice daily for 2 weeks, then 4 tablets split twice daily, for a total of 6 months of treatment.
Study: NCT06612294

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEF Interventional Session
Description: 3 sessions over 6 weeks for asthma management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PEF Interventional Session
Description: 3 sessions over 6 weeks for asthma management

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Sessions
Description: 3 sessions over 6 weeks for asthma management

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Booster
Description: A single booster session after the 6-months assessments are completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Booster
Description: A single booster session after the 6-months assessments are completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active booster
Description: A single booster session after the 6-months assessments are completed.
Study: NCT06524154

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive reinforcement
Description: normal treatment with with praising the child with encouraging words and pleasing smiles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rewarding
Description: normal treatment with giving simple gifts like stickers at the end of the procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingent escape
Description: normal treatment with giving some rest of the procedure while the child on the chair.
Study: NCT06236113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution
Description: administered at rate of 0.1 mg/kg/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution
Description: administered at rate of 0.1 mg/kg/hr
Study: NCT04758247

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TheraNova Neuromodulation System
Description: The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TheraNova Neuromodulation System
Description: The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.
Study: NCT06372314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN): this is total nutrition provided by central vein.
Description: isoleucine, leucine, valine and tryptophan intakes will be varied in the TPN solutions to study the requirements for each of these amino acids in neonates that are TPN fed.
Study: NCT04529707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Behavioral Sleep Intervention
Description: The Transdiagnostic Sleep and Circadian Intervention for Youth (TranS-CY) uses a comprehensive sleep health framework along with robust evidence for promoting healthy sleep patterns in youth. The TranS-CY incorporates best practices from numerous efficacious behavioral sleep interventions including 1) cognitive behavioral therapy, 2) interpersonal and social rhythm therapy, and 3) behavioral treatment of circadian rhythm sleep-wake disorders. The traditional TranS-CY is clinician-led and provides a robust sleep treatment framework for youth with a wide range of disorders and sleep health concerns. For this study, investigators are using the basic framework of the TranS-CY, but clinicians will train parents to incorporate the intervention into the home for their young child with DMD. Trained clinicians will work with parents to ensure the basic components of the TranS-CY are incorporated into the home-based intervention.
Study: NCT06007560

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Aerobe cycling training consisting of 12-weeks of HR-controlled training at 50-60% of VO2max (maximal oxygen uptake) for 1 hour, for 2 times (week: 1-6) to 3 times (week: 7-12) per week
Study: NCT05436639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPI-62 dose
Description: SPI-62 is an 11β hydroxysteroid dehydrogenase type 1 (HSD-1) inhibitor, supplied as oral tablets for dose 2 of drug (2mg).
Study: NCT05309694

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Paragard® T380A Intrauterine Copper Contraceptive with New Inserter
Description: Paragard® IUS with Investigational Inserter combines the current insertion tube and white rod to form a new pre-assembled inserter device that supports a single hand operation.~The device is used to pass the IUS through the cervical canal and into the uterine cavity and facilitates insertion of the T shaped Paragard® IUS implant into the uterus.
Study: NCT05902871

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eagle
Description: Direct Selective Laser Trabeculoplasty (DSLT)
Study: NCT05727748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal exercise with augmented reality
Description: The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group with augmented reality was divided into 4 sub-groups. The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed). Four stations are the same of the previous group and the other 2 stations are with augmented reality. These 2 stations worked the same cognitive and physical components but through the portable exergame platform for the elderly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal exercise
Description: The intervention program has a duration of 12 weeks with 3 sessions per week of 60 minutes each. The multimodal group was divided into 2 sub-groups. The session consisted of four stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).~The session consisted of six stations where participants simultaneously trained physical aspects (cardiorespiratory fitness, strength, balance, and flexibility) and cognitive aspects (reaction time, memory, decision making, semantics, and processing speed).

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: The control group continued their daily activities for 12 weeks and did not participate in any new physical activity program during the study.
Study: NCT04142398

Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo penile skin cell and anal swab collection

Intervention type: PROCEDURE
Intervention: High Resolution Anoscopy with Biopsy
Description: Undergo HRA with biopsy

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Intervention: Medical Examination
Description: Undergo anal and penile clinical exam
Study: NCT03817021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child intervention
Description: Through classrooms lessons cover 3 topics: 1) self-regulation, 2) hunger and fullness, and 3) mindfulness in eating and attention control practices
Study: NCT04142398

Intervention type: PROCEDURE
Intervention: Physical Examination
Description: Undergo targeted physical exam
Study: NCT04142398

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05991583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBB0979
Description: IBB0979 should be subcutaneous injected，qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBB0979
Description: IBB0979 should be subcutaneous injected，qw

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBB0979
Description: IBB0979 should be subcutaneous injected，qw
Study: NCT05462522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7303509
Description: RO7303509 will be administered as SC injection monthly, as specified in each treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7303509
Description: RO7303509 will be administered as SC injection monthly, as specified in each treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: RO7303509 matching placebo will be administered as SC injection monthly, during the MAD stage.